Allergan May Rue Mohawk Tribe Deal As Court Invalidates Restasis Patents
District court questions legitimacy of Allergan's patent transfer tactic, saying it 'could spell the end of the PTO's IPR program.'
You may also be interested in...
Allergan will split the CEO and chairman roles as requested by Appaloosa, but only in the next leadership transition. The activist shareholder fired back with renewed opposition to leaving Brent Saunders in both top jobs.
Investors want to separate the CEO and chairman roles held by Brent Saunders, among other demands, but it's unclear whether new investor Carl Icahn – a prior Saunders supporter – will pursue the same causes.
There's a lot of finger-pointing in the industry when it comes to why pharma has a bad reputation. Maybe it's time everyone who works in pharmaceuticals takes responsibility for it.